New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 27, 2012
07:31 EDTCNDOCoronado Biosciences acquires TSO manufacturing rights from Ovamed
Coronado Biosciences announced the acquisition of manufacturing rights to its lead product TSO, or Trichuris suis ova or CNDO-201, from Ovamed GmbH, for North America, South America, and Japan, Coronado's licensed territory. As part of the transaction, Coronado entered into a lease agreement to establish a manufacturing facility in Woburn, MA to produce TSO. Under the amendments, Coronado will pay Ovamed a total of $1.5M in three equal installments in 2014-2016, and, in lieu of product supply payments that would have been payable to Ovamed as the exclusive supplier, certain fees for product manufactured and sold by Coronado.
News For CNDO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 18, 2015
08:38 EDTCNDOCoronado in-licenses IV Tramadol from Revogenex Ireland
Coronado Biosciences has obtained an exclusive license to an intravenous formulation of tramadol for the U.S. market from Revogenex Ireland, a privately held company in Dublin, Ireland. Coronado has formed a wholly owned subsidiary, Avenue Therapeutics, Inc., to acquire, in-license, develop and commercialize products principally for use in the U.S. hospital market. Coronado will transfer the Revogenex license to Avenue Therapeutics, Inc. In addition to IV tramadol, Avenue Therapeutics plans to seek additional products. Tramadol is a centrally acting synthetic opioid analgesic for moderate to moderately severe pain. It is available as immediate release or extended-release tablets in the U.S. It has been reported that oral tramadol sales were approximately $1.2B in the U.S. in 2014.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use